tqb2930
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 31, 2022 (NCT05380882)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2ANTAGONIST
ERBB2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07047365 | Phase 3 | Jul 25, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06202261 | Phase 1/Phase 2 (Phase 2) | Apr 13, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05380882 | Phase 1 | May 31, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 3 | 3 | 3 | 2022 |
1 organizations
Page 1 / 1